Cargando…

Prognostic value of hepatitis B viral infection in patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era

BACKGROUND: Whether hepatitis B virus (HBV) infection poses risk to patients with nasopharyngeal carcinoma (NPC) in the intensity-modulated radiotherapy (IMRT) era remains unclear. METHODS: 953 patients with non-metastatic, newly diagnosed NPC who received detection of serologic hepatitis B surface...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Shuo-Han, Zhou, Shu, Wang, Guan-Nan, Huang, Zi-Lu, Liu, Song-Ran, Chen, Chen, Tao, Ya-Lan, Chang, Hui, Ding, Shi-Rong, Liao, Ruo-Nan, Chen, Chang, Xia, Yun-Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797573/
https://www.ncbi.nlm.nih.gov/pubmed/35116319
http://dx.doi.org/10.21037/tcr-21-1340
_version_ 1784641584361373696
author Zheng, Shuo-Han
Zhou, Shu
Wang, Guan-Nan
Huang, Zi-Lu
Liu, Song-Ran
Chen, Chen
Tao, Ya-Lan
Chang, Hui
Ding, Shi-Rong
Liao, Ruo-Nan
Chen, Chang
Xia, Yun-Fei
author_facet Zheng, Shuo-Han
Zhou, Shu
Wang, Guan-Nan
Huang, Zi-Lu
Liu, Song-Ran
Chen, Chen
Tao, Ya-Lan
Chang, Hui
Ding, Shi-Rong
Liao, Ruo-Nan
Chen, Chang
Xia, Yun-Fei
author_sort Zheng, Shuo-Han
collection PubMed
description BACKGROUND: Whether hepatitis B virus (HBV) infection poses risk to patients with nasopharyngeal carcinoma (NPC) in the intensity-modulated radiotherapy (IMRT) era remains unclear. METHODS: 953 patients with non-metastatic, newly diagnosed NPC who received detection of serologic hepatitis B surface antigen (HBsAg) and treated with IMRT were retrospectively reviewed. 171 patients had HBV infection (HBsAg seropositive). Propensity score matching method (PSM) and stabilized inverse probability of treatment weighting (IPTW) were used to address confounding. The survival rates were evaluated by Kaplan-Meier analysis and the survival curves were compared by Log-rank test. Prognostic factors were explored by multivariate analysis. RESULTS: No significant survival differences were observed between HBsAg-negative group and HBsAg-positive group [5-year overall survival (OS), 87.7% vs. 83.9%, P=0.181; locoregional recurrence-free survival (LRFS), 83.5% vs. 78.3%, P=0.109; distant metastasis-free survival (DMFS), 80.2% vs. 77.9%, P=0.446; progression-free survival (PFS), 77.4% vs. 71.4%, P=0.153], consistent with the results of PSM and IPTW analysis. Further analyses revealed that HBV infection was an independent prognostic factor for poor OS [multivariate analysis; hazard ratio (HR), 3.74; 95% confidence interval (CI), 1.45–9.68; P=0.006], LRFS (HR, 2.86; 95% CI, 1.37–5.95); P=0.005] in patients with stage N1, DMFS (HR, 2.65; 95% CI, 1.15–6.09; P=0.022) and PFS (HR, 2.63; 95% CI, 1.34–5.14; P=0.005). Among HBsAg-positive patients, liver protection improved OS (90.3% vs. 77.2%; P=0.022). CONCLUSIONS: HBV infection is an independent risk factor for patients with stage N1 NPC in the IMRT era. Hepatic protection may benefit the survival of HBsAg-positive patients.
format Online
Article
Text
id pubmed-8797573
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87975732022-02-02 Prognostic value of hepatitis B viral infection in patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era Zheng, Shuo-Han Zhou, Shu Wang, Guan-Nan Huang, Zi-Lu Liu, Song-Ran Chen, Chen Tao, Ya-Lan Chang, Hui Ding, Shi-Rong Liao, Ruo-Nan Chen, Chang Xia, Yun-Fei Transl Cancer Res Original Article BACKGROUND: Whether hepatitis B virus (HBV) infection poses risk to patients with nasopharyngeal carcinoma (NPC) in the intensity-modulated radiotherapy (IMRT) era remains unclear. METHODS: 953 patients with non-metastatic, newly diagnosed NPC who received detection of serologic hepatitis B surface antigen (HBsAg) and treated with IMRT were retrospectively reviewed. 171 patients had HBV infection (HBsAg seropositive). Propensity score matching method (PSM) and stabilized inverse probability of treatment weighting (IPTW) were used to address confounding. The survival rates were evaluated by Kaplan-Meier analysis and the survival curves were compared by Log-rank test. Prognostic factors were explored by multivariate analysis. RESULTS: No significant survival differences were observed between HBsAg-negative group and HBsAg-positive group [5-year overall survival (OS), 87.7% vs. 83.9%, P=0.181; locoregional recurrence-free survival (LRFS), 83.5% vs. 78.3%, P=0.109; distant metastasis-free survival (DMFS), 80.2% vs. 77.9%, P=0.446; progression-free survival (PFS), 77.4% vs. 71.4%, P=0.153], consistent with the results of PSM and IPTW analysis. Further analyses revealed that HBV infection was an independent prognostic factor for poor OS [multivariate analysis; hazard ratio (HR), 3.74; 95% confidence interval (CI), 1.45–9.68; P=0.006], LRFS (HR, 2.86; 95% CI, 1.37–5.95); P=0.005] in patients with stage N1, DMFS (HR, 2.65; 95% CI, 1.15–6.09; P=0.022) and PFS (HR, 2.63; 95% CI, 1.34–5.14; P=0.005). Among HBsAg-positive patients, liver protection improved OS (90.3% vs. 77.2%; P=0.022). CONCLUSIONS: HBV infection is an independent risk factor for patients with stage N1 NPC in the IMRT era. Hepatic protection may benefit the survival of HBsAg-positive patients. AME Publishing Company 2021-11 /pmc/articles/PMC8797573/ /pubmed/35116319 http://dx.doi.org/10.21037/tcr-21-1340 Text en 2021 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Original Article
Zheng, Shuo-Han
Zhou, Shu
Wang, Guan-Nan
Huang, Zi-Lu
Liu, Song-Ran
Chen, Chen
Tao, Ya-Lan
Chang, Hui
Ding, Shi-Rong
Liao, Ruo-Nan
Chen, Chang
Xia, Yun-Fei
Prognostic value of hepatitis B viral infection in patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era
title Prognostic value of hepatitis B viral infection in patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era
title_full Prognostic value of hepatitis B viral infection in patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era
title_fullStr Prognostic value of hepatitis B viral infection in patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era
title_full_unstemmed Prognostic value of hepatitis B viral infection in patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era
title_short Prognostic value of hepatitis B viral infection in patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era
title_sort prognostic value of hepatitis b viral infection in patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797573/
https://www.ncbi.nlm.nih.gov/pubmed/35116319
http://dx.doi.org/10.21037/tcr-21-1340
work_keys_str_mv AT zhengshuohan prognosticvalueofhepatitisbviralinfectioninpatientswithnasopharyngealcarcinomaintheintensitymodulatedradiotherapyera
AT zhoushu prognosticvalueofhepatitisbviralinfectioninpatientswithnasopharyngealcarcinomaintheintensitymodulatedradiotherapyera
AT wangguannan prognosticvalueofhepatitisbviralinfectioninpatientswithnasopharyngealcarcinomaintheintensitymodulatedradiotherapyera
AT huangzilu prognosticvalueofhepatitisbviralinfectioninpatientswithnasopharyngealcarcinomaintheintensitymodulatedradiotherapyera
AT liusongran prognosticvalueofhepatitisbviralinfectioninpatientswithnasopharyngealcarcinomaintheintensitymodulatedradiotherapyera
AT chenchen prognosticvalueofhepatitisbviralinfectioninpatientswithnasopharyngealcarcinomaintheintensitymodulatedradiotherapyera
AT taoyalan prognosticvalueofhepatitisbviralinfectioninpatientswithnasopharyngealcarcinomaintheintensitymodulatedradiotherapyera
AT changhui prognosticvalueofhepatitisbviralinfectioninpatientswithnasopharyngealcarcinomaintheintensitymodulatedradiotherapyera
AT dingshirong prognosticvalueofhepatitisbviralinfectioninpatientswithnasopharyngealcarcinomaintheintensitymodulatedradiotherapyera
AT liaoruonan prognosticvalueofhepatitisbviralinfectioninpatientswithnasopharyngealcarcinomaintheintensitymodulatedradiotherapyera
AT chenchang prognosticvalueofhepatitisbviralinfectioninpatientswithnasopharyngealcarcinomaintheintensitymodulatedradiotherapyera
AT xiayunfei prognosticvalueofhepatitisbviralinfectioninpatientswithnasopharyngealcarcinomaintheintensitymodulatedradiotherapyera